Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -776.30% is 82% above its 2-year average of -4266.44%, near the high end of its 2-year range (-15935.50%–-420.96%).
86.15% above its 12-month average of -5603.32%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -15935.50%.
EBITDA MARGIN
-776.30%
EBITDA MARGIN AVG TTM
-5603.32%
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+86.15%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$2.32M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.31M
EBITDA Margin
-100324.78%
TTM Avg
-75768.79%
3Y Avg
-56097.78%
5Y Avg
-38080.91%
Market Cap
$2.25M
EBITDA Margin
-866.57%
TTM Avg
-750.00%
3Y Avg
-6212.81%
5Y Avg
-4728.90%
Market Cap
$2.54M
EBITDA Margin
-163.38%
TTM Avg
-126.27%
3Y Avg
-20964.27%
5Y Avg
-20964.27%
Market Cap
$2.54M
EBITDA Margin
-372.74%
TTM Avg
-308.17%
3Y Avg
-306.11%
5Y Avg
-396.88%
Market Cap
$2.54M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.61M
EBITDA Margin
-129.25%
TTM Avg
-125.71%
3Y Avg
-160.72%
5Y Avg
-184.50%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Onconetix, Inc. (ONCO) | $2.38M | -776.30% | -5603.32% | N/A | N/A |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH)vs › | $2.32M | N/A | N/A | N/A | N/A |
| Creative Medical Technology Holdings, Inc. (CELZ)vs › | $2.31M | -100324.78% | -75768.79% | -56097.78% | -38080.91% |
| Moleculin Biotech, Inc. (MBRX)vs › | $2.45M | N/A | N/A | N/A | N/A |
| GeoVax Labs, Inc. (GOVX)vs › | $2.25M | -866.57% | -750.00% | -6212.81% | -4728.90% |
| bioAffinity Technologies, Inc. (BIAF)vs › | $2.54M | -163.38% | -126.27% | -20964.27% | -20964.27% |
| Jaguar Health, Inc. (JAGX)vs › | $2.54M | -372.74% | -308.17% | -306.11% | -396.88% |
| FibroBiologics, Inc. Common Stock (FBLG)vs › | $2.54M | N/A | N/A | N/A | N/A |
| Nuwellis, Inc. (NUWE)vs › | $2.61M | -129.25% | -125.71% | -160.72% | -184.50% |
| iSpecimen Inc. (ISPC)vs › | $2.67M | -375.69% | -244.00% | -166.51% | -121.60% |
Gross Margin
80.4%
EBITDA Margin
-776.3%
Operating Margin
-778.2%
Net Margin
-1578.8%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -15935.50% |
| 2026-03-31 | -9723.64% |
| 2025-12-31 | -420.96% |
| 2025-09-30 | -680.34% |
| 2025-06-30 | -1256.14% |
| 2025-03-31 | -1621.65% |
| 2024-12-31 | -4076.90% |
| 2024-09-30 | -600.16% |
| 2024-06-30 | -1903.07% |
| 2024-03-31 | -1552.65% |
| 2023-12-31 | -9159.76% |
